Friday, May 1, 2026

That Eye Twitch Might Be More Than Stress—Here’s What to Know

Facial spasms, common in younger adults, may signal neurological issues. Prompt diagnosis and treatment are crucial for quality of life.

How ExcelOs Inject Revolutionizes Bone Grafting: Insights from the Latest GBR Seminar

CGBIO hosted a hands-on seminar for dental professionals, focusing on practical skills in maxillary sinus lifts and bone grafting techniques.

Is Former President Yoon Seok Yeol Involved? The Shocking Truth Behind the North Korean Remittance Case

Investigations into witness coercion allegations against prosecutors in the North Korea remittance case and political manipulation continue.

Tag: botulinum toxin

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Hugel holds ‘Letybo’ training in Indonesia to boost competitiveness and brand awareness

Hugel expands in Indonesia with a training program for Letybo, enhancing local medical professionals' skills and brand loyalty.

Hugel holds first regional symposium in Beijing, to tour key cities including Shanghai and Guangzhou

Hugel held a successful symposium in Beijing to enhance awareness of its Letybo product among Chinese medical professionals.

INIBO Launch: How This New Botulinum Toxin is Transforming the Aesthetic Market in Peru

Inibio launched its botulinum toxin product Inibo in Peru, marking a significant entry into the Latin American medical aesthetics market.

Huons BioPharma’s Botulinum Toxin HUTOX Set to Transform the Chinese Market

Huons BioPharma partners with iMaker Technology to supply botulinum toxin, aiming for a strong market presence in China.

Discover the Excellence of Botulax and Revolax at Thailand’s Largest Dermatology Conference

Hugel showcased its HA filler Revolax and botulinum toxin products at Thailand's largest dermatology conference, enhancing medical engagement.

Hugel’s Record-Breaking 2025 Financials: How Botulax and HA Fillers Drive 14% Revenue Growth

Hugel reports record 2025 financials with strong sales in toxins, fillers, and cosmetics, focusing on global market expansion.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.